Activating pyruvate kinase R

Patent metadata

Field	Value
Publication number	US-11844787-B2
Application number	US-202117351389-A
Country	US
Kind code	B2
Filing date	Jun 18, 2021
Priority date	Sep 19, 2018
Publication date	Dec 19, 2023
Grant date	Dec 19, 2023

Abstract

This disclosure provides compounds and compositions for activating pyruvate kinase R (PKR) and related methods of manufacturing and using these compounds and compositions.

First claim

We claim:

1. A compound of formula:

or a pharmaceutically acceptable salt thereof.

2. A compound of formula:

3. A pharmaceutical composition comprising the compound of claim 1 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

4. A pharmaceutical composition comprising the compound of claim 2 and a pharmaceutically acceptable carrier.

Assignees

• Novo Nordisk Healthcare Ag

Inventors

• Ericsson Anna
• Green Neal
• Gustafson Gary
• Lancia Jr David R
• Marshall Gary
• Mitchell Lorna
• Richard David
• Wang Zhongguo

Classifications

• A61K31/436 Primary

  the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin · CPC title

• A61K9/0053

  Mouth and digestive tract, i.e. intraoral and peroral administration · CPC title

• A61P7/06

  Antianaemics · CPC title

• C07D487/04

  Ortho-condensed systems · CPC title

• C07D491/056

  with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring · CPC title